Population pharmacokinetic modeling of GS‐441524, the active metabolite of remdesivir, in Japanese COVID‐19 patients with renal dysfunction-Reference-Cited by-同舟云学术

Population pharmacokinetic modeling of GS‐441524, the active metabolite of remdesivir, in Japanese COVID‐19 patients with renal dysfunction

Published:2021-11-18 Issue:1 Volume:11 Page:94-103
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacom & Syst Pharma

Author:

Sukeishi Asami¹,Itohara Kotaro¹,Yonezawa Atsushi¹²,Sato Yuki¹,Matsumura Katsuyuki¹,Katada Yoshiki¹,Nakagawa Takayuki¹,Hamada Satoshi³,Tanabe Naoya³,Imoto Eishi⁴,Kai Shinichi⁵,Hirai Toyohiro³,Yanagita Motoko⁶⁷,Ohtsuru Shigeru⁸,Terada Tomohiro¹,Ito Isao³

Affiliation:

1. Department of Clinical Pharmacology and Therapeutics Kyoto University Hospital Kyoto Japan

2. Graduate School of Pharmaceutical Sciences Kyoto University Kyoto Japan

3. Department of Respiratory Medicine Graduate School of Medicine Kyoto University Kyoto Japan

4. Shimadzu Corporation Kyoto Japan

5. Department of Anesthesia Kyoto University Hospital Kyoto Japan

6. Department of Nephrology Graduate School of Medicine Kyoto University Kyoto Japan

7. Institute for the Advanced Study of Human Biology (WPI‐ASHBi) Kyoto University Kyoto Japan

8. Department of Primary Care and Emergency Medicine Graduate School of Medicine Kyoto University Kyoto Japan

Funder

Kyoto University

Publisher

Wiley

Subject

Pharmacology (medical),Modeling and Simulation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12736

Reference24 articles.

1. Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19

2. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus

3. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan

4. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

5. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transient Lactic Acidosis and Elevation of Transaminases after the Introduction of Remdesivir in a Patient with Acute Kidney Injury;Case Reports in Critical Care;2024-02-22

2. Pharmacokinetics of GS-441524, the active metabolite of remdesivir, in patients receiving continuous renal replacement therapy: A case series;Journal of Infection and Chemotherapy;2023-10

3. Exploration of the optimal GS-441524 trough concentration for treating COVID-19;International Journal of Antimicrobial Agents;2023-08

4. Population pharmacokinetics and exposure–clinical outcome relationship of remdesivir major metabolite GS‐441524 in patients with moderate and severe COVID‐19;CPT: Pharmacometrics & Systems Pharmacology;2023-02-22

5. Safety Evaluation of Remdesivir for COVID-19 Patients with eGFR < 30 mL/min without Renal Replacement Therapy in a Japanese Single-Center Study;Healthcare;2022-11-17